Team
Experienced builders at the intersection of science, medicine, and capital.
The Ligase BioPartners team brings decades of expertise in life sciences venture capital, strategic guidance, and operational support needed to accelerate development of early stage innovation.
Cheryl Zimberlin, Ph.D
Cheryl is the former Investment Director at M Ventures, where she led Seed and Series A investments in Calypso Biotech, Rewind Therapeutics, Outrun Therapeutics, Multitude Therapeutics, ImmuneBridge, and several other emerging life science companies.
Her track record includes successful exits such as Calypso (acquired by Novartis) and VAXXIM (acquired by NEC/BCME). Cheryl holds a Ph.D. in Oncology from the University of Amsterdam and serves on the Board of Directors of Laigo Bio.
Shobhit Dhawan, Ph.D
Shobhit is the former Managing Director of the Oncode Oncology Bridge Fund I, where he built and financed early-stage therapeutic and platform companies emerging from the Oncode Institute. Previously, he was an Investment Manager at Amsterdam Academic Ventures, focusing on company creation and early financings across life sciences and technology.
Shobhit holds a Ph.D. in Immunology from the University of Amsterdam and serves on the Board of Directors of sCellgen, 51x Therapeutics, Genase Therapeutics, and Simmunext Biotherapeutics.